Apollomics
Foster City · Founded 2016
About Apollomics
Apollomics is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including the novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $274.7M
- Funding stage: IPO
- Last round: Post-IPO Debt (Mar 2026)
- Ticker: nasdaq:APLM
- Website: apollomicsinc.com
- Phone: +1-650-209-4055
Industries & Categories
Biotechnology, Health Care, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/apollomics-67277 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.